Doug Ingram has served as President, CEO, and board member since 2017. He has no ambiguity about Sarepta’s mission:
“We know why we get up every day and work as hard as we do. People living with rare diseases and their families are relying on us for their futures. We’re in a position to extend and change the lives of so many people. The opportunity to do good is just breathtaking.”
Doug has a single-minded focus to make Sarepta the leader in precision genetic medicine and rescue lives devastated by rare genetic disease. “I saw something in Sarepta that was special. An opportunity to be part of something important. Much of what we’re doing has never been done before. It has the potential to upend the entire medical system.”
Doug likes to make clear that Sarepta is different from most biotechs clustered around Kendall Square in Cambridge. “We’re a commercial-stage organization with the resources to bring precision genetic medicine from discovery all the way to the patient.”
Doug’s two decades in the pharma-biotech world began at Allergan, which he joined as General Counsel in 2001, holding positions of increasing responsibility until being named President in 2013. When Allergan was acquired by Actavis in 2016, he moved on to Chase Pharmaceuticals, serving as President and CEO before coming to Sarepta.
Doug received his JD from the University of Arizona and his BS from Arizona State University. He sits on Relay Therapeutics’ Board of Directors.
What is Douglas S. Ingram's net worth?
The estimated net worth of Douglas S. Ingram is at least $47.97 million as of November 3rd, 2023. Mr. Ingram owns 390,307 shares of Sarepta Therapeutics stock worth more than $47,968,730 as of December 26th. This net worth estimate does not reflect any other assets that Mr. Ingram may own. Additionally, Mr. Ingram receives a salary of $1,620,000.00 as CEO at Sarepta Therapeutics. Learn More about Douglas S. Ingram's net worth.
How old is Douglas S. Ingram?
What is Douglas S. Ingram's salary?
How do I contact Douglas S. Ingram?
Has Douglas S. Ingram been buying or selling shares of Sarepta Therapeutics?
Douglas S. Ingram has not been actively trading shares of Sarepta Therapeutics during the past quarter. Most recently, on Friday, November 3rd, Douglas S. Ingram bought 25,225 shares of Sarepta Therapeutics stock. The stock was acquired at an average cost of $79.36 per share, with a total value of $2,001,856.00. Following the completion of the transaction, the chief executive officer now directly owns 390,307 shares of the company's stock, valued at $30,974,763.52. Learn More on Douglas S. Ingram's trading history.
Who are Sarepta Therapeutics' active insiders?
Sarepta Therapeutics' insider roster includes Bilal Arif (EVP, Chief Technical Operations Officer), Richard Barry (Director), M. Behrens (Director), Kathryn Boor (Director), Joseph Bratica (Insider), Ryan Brown (EVP), Michael Chambers (Director), Ian Estepan (EVP, Chief Financial Officer), David Howton (EVP), Douglas Ingram (CEO), Stephen Mayo (Director), Dallan Murray (EVP, Chief Customer Officer), Louise Rodino-Klapac (Insider), and Hans Wigzell (Director). Learn More on Sarepta Therapeutics' active insiders.
Are insiders buying or selling shares of Sarepta Therapeutics?
In the last twelve months, Sarepta Therapeutics insiders bought shares 1 times. They purchased a total of 37,038 shares worth more than $4,955,684.40. In the last twelve months, insiders at the biotechnology company sold shares 11 times. They sold a total of 90,668 shares worth more than $13,164,125.22. The most recent insider tranaction occured on December, 12th when Director Hans Lennart Rudolf Wigzell sold 10,500 shares worth more than $1,310,820.00. Insiders at Sarepta Therapeutics own 7.7% of the company.
Learn More about insider trades at Sarepta Therapeutics. Information on this page was last updated on 12/12/2024.
